Low-density lipoprotein encapsulated thiosemicarbazone metal complexes is active targeting vehicle for breast, lung, and prostate cancers

References

• Abdellatif AA, Zayed G, El-Bakry A, et al. (2016). Novel gold nanoparticles coated with somatostatin as a potential delivery system for targeting somatostatin receptors. Drug Dev Ind Pharm 42:1782–91.
   PubMed Web of Science ®Google Scholar
• Abdellatif AAH. (2020). A plausible way for excretion of metal nanoparticles via active targeting. Drug Dev Ind Pharm 46:744–50.
   PubMed Web of Science ®Google Scholar
• Abdellatif AAH, Alturki HNH, Tawfeek HM. (2021a). Different cellulosic polymers for synthesizing silver nanoparticles with antioxidant and antibacterial activities. Sci Rep 11:84.
   PubMed Web of Science ®Google Scholar
• Abdellatif AAH, Khan RA, Alhowail AH, et al. (2021b). Octreotide-conjugated silver nanoparticles for active targeting of somatostatin receptors and their application in a nebulized rat model. Nanotechnol Rev 11:266–83.
   Web of Science ®Google Scholar
• Abdolmaleki A, Asadi A, Gurushankar K, et al. (2020). Importance of nano medicine and new drug therapies for cancer. Adv Pharm Bull 11:450–7.
   PubMed Web of Science ®Google Scholar
• Afrasiabi Z, Sinn E, Chen J, et al. (2004). Appended 1,2-naphthoquinones as anticancer agents 1: synthesis, structural, spectral and antitumor activities of ortho-naphthaquinone thiosemicarbazone and its transition metal complexes. Inorg Chim Acta 357:271–8.
   Web of Science ®Google Scholar
• Ahmad F, Sun Q, Patel D, Stommel JM. (2019). Cholesterol metabolism: a potential therapeutic target in glioblastoma. Cancers (Basel) 11:146.
   PubMed Web of Science ®Google Scholar
• Alhadad L, Harisa G, Alanazi F. (2020). Design and encapsulation of anticancer dual HSP27 and HER2 inhibitor into low density lipoprotein to target ovarian cancer cells. Saudi Pharm J 28:387–96.
   PubMed Web of Science ®Google Scholar
• Alhadad LAJ. (2021). Encapsulation and in vitro evaluation of low-density lipoprotein with cholesterol conjugated anti-HSP27 and HER2 proteins as drug delivery enhancement in ovarian cancer. Biomed J Sci Tech Res 35:27497–504.
   Google Scholar
• Ali MS, Hasan M. (2021). Chelating activity of (2E,2’E)-2,2’-(pyridine-2,6-diylbis(ethan-1-yl-1-ylidene)bis(N-ethylhydrazinecarbothioamide). J Mol Struct 1238:130436.
   Web of Science ®Google Scholar
• Altıntop MD, Atlı Ö, Ilgın S, et al. (2016). Synthesis and biological evaluation of new naphthalene substituted thiosemicarbazone derivatives as potent antifungal and anticancer agents. Eur J Med Chem 108:406–14.
   PubMed Web of Science ®Google Scholar
• Chaudhary J, Bower J, Corbin IR. (2019). Lipoprotein drug delivery vehicles for cancer: rationale and reason. IJMS 20:6327.
   Web of Science ®Google Scholar
• Chen J, Corbin IR, Li H, et al. (2007). Ligand conjugated low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo. J Am Chem Soc 129:5798–9.
   PubMed Web of Science ®Google Scholar
• Chung NS, Wasan KM. (2004). Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv Drug Deliv Rev 56:1315–34.
   PubMed Web of Science ®Google Scholar
• Di L, Maiseyeu A. (2021). Low-density lipoprotein nanomedicines: mechanisms of targeting, biology, and theranostic potential. Drug Deliv 28:408–21.
   PubMed Web of Science ®Google Scholar
• Firestone RA. (1994). Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug Chem 5:105–13.
   PubMed Web of Science ®Google Scholar
• Gallagher EJ, Zelenko Z, Neel BA, et al. (2017). Elevated tumor LDLR expression accelerates LDL cholesterol-mediated breast cancer growth in mouse models of hyperlipidemia. Oncogene 36:6462–71.
   PubMed Web of Science ®Google Scholar
• Guan X, Liu Z, Zhao Z, et al. (2019). Emerging roles of low-density lipoprotein in the development and treatment of breast cancer. Lipids Health Dis 18:137.
   PubMed Web of Science ®Google Scholar
• Harisa GI, Alanazi FK. (2014). Low density lipoprotein bionanoparticles: from cholesterol transport to delivery of anti-cancer drugs. Saudi Pharm J 22:504–15.
   PubMed Web of Science ®Google Scholar
• Huang J-L, Jiang G, Song Q-X, et al. (2017). Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis. Nat Commun 8:15144.
   PubMed Web of Science ®Google Scholar
• Jaragh-Alhadad LA, Falahati M. (2022). Tin oxide nanoparticles trigger the formation of amyloid β oligomers/protofibrils and underlying neurotoxicity as a marker of Alzheimer’s diseases. Int J Biol Macromol 204:154–60.
   PubMed Web of Science ®Google Scholar
• Kader A, Pater A. (2002). Loading anticancer drugs into HDL as well as LDL has little effect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J Control Release 80:29–44.
   PubMed Web of Science ®Google Scholar
• Lee JY, Kim JH, Bae KH, et al. (2015). Low-density lipoprotein-mimicking nanoparticles for tumor-targeted theranostic applications. Small 11:222–31.
   PubMed Web of Science ®Google Scholar
• Li M, Ma S, Xie X, et al. (2021). Vincristine-doxorubicin co-loaded artificial low-density lipoproteins towards solid tumours. Eur J Med Chem 226:113802.
   PubMed Web of Science ®Google Scholar
• Li R, Liu B, Liu Y, et al. (2020). Elevated serum lipid level can serve as early signal for metastasis for Non-Small Cell Lung Cancer patients: a retrospective nested case-control study. J Cancer 11:7023–31.
   PubMed Web of Science ®Google Scholar
• Nakayama T, Butler JS, Sehgal A, et al. (2012). Harnessing a physiologic mechanism for siRNA delivery with mimetic lipoprotein particles. Mol Ther 20:1582–9.
   PubMed Web of Science ®Google Scholar
• Nikanjam M, Blakely EA, Bjornstad KA, et al. (2007). Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int J Pharm 328:86–94.
   PubMed Web of Science ®Google Scholar
• Paterson BM, Donnelly PS. (2011). Copper complexes of bis(thiosemicarbazones): from chemotherapeutics to diagnostic and therapeutic radiopharmaceuticals. Chem Soc Rev 40:3005–18.
   PubMed Web of Science ®Google Scholar
• Pinzón-Daza M, Garzón R, Couraud P, et al. (2012). The association of statins plus LDL receptor-targeted liposome-encapsulated doxorubicin increases in vitro drug delivery across blood-brain barrier cells. Br J Pharmacol 167:1431–47.
   PubMed Web of Science ®Google Scholar
• Shakya B, Yadav PN. (2020). Thiosemicarbazones as potent anticancer agents and their modes of action. Mini Rev Med Chem 20:638–61.
   PubMed Web of Science ®Google Scholar
• Shao J, Ma ZY, Li A, et al. (2014). Thiosemicarbazone Cu(II) and Zn(II) complexes as potential anticancer agents: syntheses, crystal structure, DNA cleavage, cytotoxicity and apoptosis induction activity. J Inorg Biochem 136:13–23.
   PubMed Web of Science ®Google Scholar
• Shaw W. (1961). Cation toxicity and the stability of transition-metal complexes. Nature 192:754–5.
   PubMed Web of Science ®Google Scholar
• Stopsack KH, Gerke TA, Andrén O, et al. (2017). Cholesterol uptake and regulation in high-grade and lethal prostate cancers. Carcinogenesis 38:806–11.
   PubMed Web of Science ®Google Scholar
• Sun P, Zhang N, Hua H, et al. (2017). Low density lipoprotein peptide conjugated submicron emulsions for combating prostate cancer. Biomed Pharmacother 86:612–9.
   PubMed Web of Science ®Google Scholar
• Tang L, Li J, Zhao Q, et al. (2021). Advanced and innovative nano-systems for anticancer targeted drug delivery. Pharmaceutics 13:1151.
   PubMed Web of Science ®Google Scholar
• Tania M, Khan MA, Song Y. (2010). Association of lipid metabolism with ovarian cancer. Curr Oncol 17:6–11.
   PubMed Web of Science ®Google Scholar
• Varghese NM, Senthil V, Saxena SK. (2018). Nanocarriers for brain specific delivery of anti-retro viral drugs: challenges and achievements. J Drug Target 26:195–207.
   PubMed Web of Science ®Google Scholar
• Verma M, Sheoran P, Chaudhury A. (2018). Application of nanotechnology for cancer treatment. In: Gahlawat S, Duhan J, Salar R, Siwach P, Kumar S, Kaur P, ed. Advances in animal biotechnology and its applications. Singapore: Springer.
   Google Scholar
• Wang C, Li P, Xuan J, et al. (2017). Cholesterol enhances colorectal cancer progression via ROS elevation and MAPK signaling pathway activation. Cell Physiol Biochem 42:729–42.
   PubMed Web of Science ®Google Scholar
• Wang Z, Duan X, Lv Y, Zhao Y. (2019). Low density lipoprotein receptor (LDLR)-targeted lipid nanoparticles for the delivery of sorafenib and Dihydroartemisinin in liver cancers. Life Sci 239:117013.
   PubMed Web of Science ®Google Scholar
• Xavier JS, Jayabalan K, Ragavendran V, NityanandaShetty A. (2020). Syntheses, quantum mechanical modeling, biomolecular interaction and in vitro anticancer - Tubulin activity of thiosemicarbazones. Bioorg Chem 102:104081.
   PubMed Web of Science ®Google Scholar
• Zhang N, Tao J, Hua H, et al. (2015). Low-density lipoprotein peptide-combined DNA nanocomplex as an efficient anticancer drug delivery vehicle. Eur J Pharm Biopharm 94:20–9.
   PubMed Web of Science ®Google Scholar
• Zhang X, Huang G. (2017). Synthetic lipoprotein as nano-material vehicle in the targeted drug delivery. Drug Deliv 24:16–21.
   PubMed Web of Science ®Google Scholar
• Zhao L, Zhan H, Jiang X, et al. (2019). The role of cholesterol metabolism in leukemia. Blood Sci 1:44–9.
   PubMedGoogle Scholar
• Zhou P, Hatziieremia S, Elliott MA, et al. (2010). Uptake of synthetic Low Density Lipoprotein by leukemic stem cells - a potential stem cell targeted drug delivery strategy. J Control Release 148:380–7.
   PubMed Web of Science ®Google Scholar